222 related articles for article (PubMed ID: 26370694)
1. Image-driven pharmacokinetics: nanomedicine concentration across space and time.
Brill DA; MacKay JA
Nanomedicine (Lond); 2015; 10(18):2861-79. PubMed ID: 26370694
[TBL] [Abstract][Full Text] [Related]
2. Imaging-guided revival of nanomedicine?
Senders ML; Fayad ZA; Reiner T; Mulder WJ; Pérez-Medina C
Nanomedicine (Lond); 2017 Jan; 12(2):89-90. PubMed ID: 27876441
[No Abstract] [Full Text] [Related]
3. Specificity of pharmacokinetic modeling of nanomedicines.
Lebreton V; Legeay S; Saulnier P; Lagarce F
Drug Discov Today; 2021 Oct; 26(10):2259-2268. PubMed ID: 33892140
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography image-guided drug delivery: current status and future perspectives.
Chakravarty R; Hong H; Cai W
Mol Pharm; 2014 Nov; 11(11):3777-97. PubMed ID: 24865108
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, in vitro and in vivo evaluation of radiolabeled nanoparticles.
Shokeen M; Fettig NM; Rossin R
Q J Nucl Med Mol Imaging; 2008 Sep; 52(3):267-77. PubMed ID: 18475250
[TBL] [Abstract][Full Text] [Related]
6. Molecular imaging in nanomedicine - A developmental tool and a clinical necessity.
Dearling JLJ; Packard AB
J Control Release; 2017 Sep; 261():23-30. PubMed ID: 28624600
[TBL] [Abstract][Full Text] [Related]
7. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic considerations for targeted drug delivery.
Yamashita F; Hashida M
Adv Drug Deliv Rev; 2013 Jan; 65(1):139-47. PubMed ID: 23280371
[TBL] [Abstract][Full Text] [Related]
9. [Molecular imaging-based early-phase and exploratory clinical research].
Watanabe Y
Yakugaku Zasshi; 2013; 133(2):187-95. PubMed ID: 23370512
[TBL] [Abstract][Full Text] [Related]
10. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles.
Liu Y; Miyoshi H; Nakamura M
Int J Cancer; 2007 Jun; 120(12):2527-37. PubMed ID: 17390371
[TBL] [Abstract][Full Text] [Related]
11. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective.
Moghimi SM; Hunter AC; Andresen TL
Annu Rev Pharmacol Toxicol; 2012; 52():481-503. PubMed ID: 22035254
[TBL] [Abstract][Full Text] [Related]
12. Insight into nanoparticle cellular uptake and intracellular targeting.
Yameen B; Choi WI; Vilos C; Swami A; Shi J; Farokhzad OC
J Control Release; 2014 Sep; 190():485-99. PubMed ID: 24984011
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, Metabolism, Distribution and Permeability of Nanomedicine.
Ravindran S; Suthar JK; Rokade R; Deshpande P; Singh P; Pratinidhi A; Khambadkhar R; Utekar S
Curr Drug Metab; 2018; 19(4):327-334. PubMed ID: 29512450
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and biodistribution of nanoparticles.
Li SD; Huang L
Mol Pharm; 2008; 5(4):496-504. PubMed ID: 18611037
[TBL] [Abstract][Full Text] [Related]
15. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders.
Muthu MS; Singh S
Nanomedicine (Lond); 2009 Jan; 4(1):105-18. PubMed ID: 19093899
[TBL] [Abstract][Full Text] [Related]
16. Designed multifunctional polymeric nanomedicines: long-term biodistribution and tumour accumulation of aptamer-targeted nanomaterials.
Fletcher NL; Houston ZH; Simpson JD; Veedu RN; Thurecht KJ
Chem Commun (Camb); 2018 Oct; 54(82):11538-11541. PubMed ID: 30182121
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticles for brain-specific drug and genetic material delivery, imaging and diagnosis.
Posadas I; Monteagudo S; Ceña V
Nanomedicine (Lond); 2016 Apr; 11(7):833-49. PubMed ID: 26980585
[TBL] [Abstract][Full Text] [Related]
18. Approaches using molecular imaging technology -- use of PET in clinical microdose studies.
Wagner CC; Langer O
Adv Drug Deliv Rev; 2011 Jun; 63(7):539-46. PubMed ID: 20887762
[TBL] [Abstract][Full Text] [Related]
19. Applications for site-directed molecular imaging agents coupled with drug delivery potential.
Wang H; Chen X
Expert Opin Drug Deliv; 2009 Jul; 6(7):745-68. PubMed ID: 19552614
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting toxicity and efficacy of polymeric nanomedicines.
Igarashi E
Toxicol Appl Pharmacol; 2008 May; 229(1):121-34. PubMed ID: 18355886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
